Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Fontein DBY, Houtsma D, Hille ETM, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JMS, Nortier JWR, van de Velde CJH; Dutch TEAM Steering Committee. Fontein DBY, et al. Among authors: houtsma d. Ann Oncol. 2012 Dec;23(12):3091-3097. doi: 10.1093/annonc/mds204. Epub 2012 Aug 2. Ann Oncol. 2012. PMID: 22865782 Free article.
Pharmacogenetics in oncology: a promising field.
Houtsma D, Guchelaar HJ, Gelderblom H. Houtsma D, et al. Curr Pharm Des. 2010;16(2):155-63. doi: 10.2174/138161210790112719. Curr Pharm Des. 2010. PMID: 20205661 Review.
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ. Fontein DB, et al. Among authors: houtsma d. Breast Cancer Res Treat. 2014 Apr;144(3):599-606. doi: 10.1007/s10549-014-2873-2. Epub 2014 Mar 4. Breast Cancer Res Treat. 2014. PMID: 24590773 Clinical Trial.
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR. de Groot S, et al. Among authors: houtsma d. BMC Cancer. 2015 Oct 5;15:652. doi: 10.1186/s12885-015-1663-5. BMC Cancer. 2015. PMID: 26438237 Free PMC article. Clinical Trial.
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U. Diekstra MH, et al. Among authors: houtsma d. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28571114 Free PMC article. Clinical Trial.
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Cats A, et al. Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650363 Clinical Trial.
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. Hulshof EC, et al. Among authors: houtsma d. Eur J Cancer. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998046 Free article.
Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia - a randomized controlled trial.
Lugtenberg RT, van den Hurk CJG, Smorenburg CH, Mosch L, Houtsma D, Deursen MAGDH, Kaptein AA, Gelderblom H, Kroep JR. Lugtenberg RT, et al. Among authors: houtsma d. Support Care Cancer. 2022 Aug;30(8):6641-6648. doi: 10.1007/s00520-022-07090-7. Epub 2022 May 2. Support Care Cancer. 2022. PMID: 35501515 Free PMC article. Clinical Trial.
28 results